- Home
- VSCO vs CNTA Comparison
VSCO vs CNTA Comparison
Compare VSCO & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSCO
- CNTA
- Stock Information
- Founded
- VSCO 1977
- CNTA 2020
- Country
- VSCO United States
- CNTA United Kingdom
- Employees
- VSCO N/A
- CNTA N/A
- Industry
- VSCO Clothing/Shoe/Accessory Stores
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- VSCO Consumer Discretionary
- CNTA Health Care
- Exchange
- VSCO Nasdaq
- CNTA Nasdaq
- Market Cap
- VSCO 1.9B
- CNTA 1.6B
- IPO Year
- VSCO N/A
- CNTA 2021
- Fundamental
- Price
- VSCO $19.43
- CNTA $14.29
- Analyst Decision
- VSCO Hold
- CNTA Strong Buy
- Analyst Count
- VSCO 12
- CNTA 10
- Target Price
- VSCO $26.50
- CNTA $28.78
- AVG Volume (30 Days)
- VSCO 3.4M
- CNTA 992.4K
- Earning Date
- VSCO 08-27-2025
- CNTA 08-12-2025
- Dividend Yield
- VSCO N/A
- CNTA N/A
- EPS Growth
- VSCO 55.42
- CNTA N/A
- EPS
- VSCO 2.07
- CNTA N/A
- Revenue
- VSCO $6,224,000,000.00
- CNTA $15,000,000.00
- Revenue This Year
- VSCO $2.23
- CNTA N/A
- Revenue Next Year
- VSCO $1.77
- CNTA N/A
- P/E Ratio
- VSCO $9.24
- CNTA N/A
- Revenue Growth
- VSCO 1.47
- CNTA 118.88
- 52 Week Low
- VSCO $13.76
- CNTA $9.00
- 52 Week High
- VSCO $48.73
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- VSCO 46.40
- CNTA 61.38
- Support Level
- VSCO $19.57
- CNTA $13.22
- Resistance Level
- VSCO $20.62
- CNTA $14.74
- Average True Range (ATR)
- VSCO 0.99
- CNTA 0.73
- MACD
- VSCO 0.11
- CNTA 0.14
- Stochastic Oscillator
- VSCO 39.44
- CNTA 85.11
About VSCO Victorias Secret & Co.
Victoria's Secret & Co is a retailer of women's intimate and other apparel and beauty products marketed under the Victoria's Secret, PINK, and Adore Me brand names. It also includes the merchandise sourcing and production function serving the Company and its international partners. The Company operates as a single segment designed to serve customers seamlessly through stores and online channels.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.